Share-Based Payments (Tables)

9 Months Ended

Sep. 30, 2015

The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2015			2014			2015			2014
Research and development	$	10.8		$	24.2		$	68.3		$	78.1
Selling, general and administrative	17.5			34.7			99.3			115.5
Subtotal	28.3			58.9			167.6			193.6
Capitalized share-based compensation costs	(2.8		)	(2.3		)	(8.4		)	(7.5		)
Share-based compensation expense included in total cost and expenses	25.5			56.6			159.2			186.1
Income tax effect	(6.4		)	(16.6		)	(46.0		)	(55.4		)
Share-based compensation expense included in net income attributable to Biogen Inc.	$	19.1		$	40.0		$	113.2		$	130.7

The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2015			2014			2015			2014
Market stock units	$	7.3		$	7.1		$	33.4		30.2
Time-vested restricted stock units	30.4			28.2			94.1			86.6
Cash settled performance units	(9.5		)	15.2			17.5			50.6
Performance units	(2.8		)	5.7			11.6			16.0
Employee stock purchase plan	2.9			2.7			11.0			10.2
Subtotal	28.3			58.9			167.6			193.6
Capitalized share-based compensation costs	(2.8		)	(2.3		)	(8.4		)	(7.5		)
Share-based compensation expense included in total cost and expenses	$	25.5		$	56.6		$	159.2		$	186.1

The following table summarizes our equity grants to employees, officers and directors under our current stock plans:



	For the Nine Months Ended September 30,
	2015	2014
Market stock units	181,000	236,000
Cash settled performance shares	115,000	182,000
Performance units	89,000	57,000
Time-vested restricted stock units	393,000	437,000